Embecta Corp. Common Stock
EMBCEmbecta Corp. (EMBC) is a global diabetes care company focused on providing innovative medical products and solutions. Originally part of Becton, Dickinson and Company (BD), Embecta became an independent entity specializing in diabetes management, including insulin delivery devices and related products. The company aims to improve the quality of life for individuals with diabetes through its portfolio of trusted, high-quality healthcare solutions.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 15, 2026 | $0.01 | 2026-05-28 | 2026-05-28 |
| March 17, 2026 | $0.15 | 2026-02-27 | 2026-02-27 |
| December 18, 2025 | $0.15 | 2025-12-05 | 2025-12-05 |
| September 15, 2025 | $0.15 | 2025-08-29 | 2025-08-29 |
| June 13, 2025 | $0.15 | 2025-05-28 | 2025-05-28 |
Dividends Summary
- Consistent Payer: Embecta Corp. Common Stock has rewarded shareholders with 16 dividend payments over the past 4 years.
- Total Returned Value: Investors who held EMBC shares during this period received a total of $2.26 per share in dividend income.
- Latest Payout: The most recent dividend of $0.01/share was paid 33 days ago, on June 15, 2026.
- Yield & Schedule: EMBC currently pays dividends quarterly with an annual yield of 14.15%.
- Dividend Growth: Since 2022, the dividend payout has decreased by 93.3%, from $0.15 to $0.01.
Company News
Embecta Corp. (EMBC) faces a securities class action lawsuit for allegedly concealing material risks to its pen needle business. The company provided reassuring guidance in February 2026 but reported a shocking 61% sequential EPS decline in Q2 2026, with pen needle revenues suffering massive declines. Embecta slashed its full-year EPS guidance by...
A class action lawsuit has been filed against Embecta Corp. alleging that the company made materially false and misleading statements about its business and guidance during the period from November 25, 2025 to May 4, 2026. The complaint claims Embecta's pen needle business guidance was unattainable, and the company subsequently missed Q2 2026 exp...
Rosen Law Firm is soliciting investors who purchased shares of Embecta Corp., Nano-X Imaging Ltd., and Lucid Group, Inc. during specified periods to join securities class action lawsuits. The lawsuits allege that these companies made false or misleading statements regarding financial guidance and business performance. Investors with losses exceed...
Embecta Corp. faces a securities fraud class action lawsuit after revealing a 14% revenue decline due to weakness in pen needle sales and lowering fiscal 2026 guidance on May 5, 2026. The stock plummeted 57.8% to $3.90 per share. Defendants are accused of making materially false statements and failing to disclose material adverse facts about the ...
A securities class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) alleging that the company made false and misleading statements about its financial guidance. Embecta's stock plummeted 57.8% on May 5, 2026, after the company disclosed a revenue decline of over 14% and cut its fiscal year 2026 guidance, primarily due to weaknes...
